PSA, PCA3 and the phi losophy of prostate cancer management

@inproceedings{Melichar2013PSAPA,
  title={PSA, PCA3 and the phi losophy of prostate cancer management},
  author={B. Melichar},
  booktitle={Clinical chemistry and laboratory medicine},
  year={2013}
}
  • B. Melichar
  • Published in
    Clinical chemistry and…
    2013
  • Medicine
  • The fundamental role that laboratory medicine currently takes in the management of cancer patients [ 1 ] is probably more visible in prostate cancer than any other tumor [ 2 ]. In patients with prostate cancer, laboratory medicine plays not only a crucial role in the early diagnosis, but also has a major impact on subsequent phases of the management of the patient throughout the entire course of the disease. The advent of prostate specific antigen (PSA) testing has transformed the management of… CONTINUE READING
    8 Citations
    Thiosulfate in urine: new hope or new failure of a biomarker for prostate cancer?
    • 5
    • PDF
    Emerging biomarkers in the detection and prognosis of prostate cancer
    • 23
    • PDF
    PSA in screening for prostate cancer: more good than harm or more harm than good?
    • M. Duffy
    • Medicine
    • Advances in clinical chemistry
    • 2014
    • 25
    miRNAs as novel biomarkers in the management of prostate cancer
    • 62
    Diagnosis of prostate cancer via nanotechnological approach
    • 15
    • PDF
    RecQ helicase BLM regulates prostate cancer cell proliferation and apoptosis
    • 10
    • PDF
    Predictions for the future of kallikrein-related peptidases in molecular diagnostics
    • 16
    • PDF

    References

    SHOWING 1-10 OF 51 REFERENCES
    Tumor biomarkers: PSA and beyond
    • B. Melichar
    • Medicine
    • Clinical chemistry and laboratory medicine
    • 2012
    • 7
    • PDF
    Human epididymis protein 4: the start of a post-ROMAn era?
    • B. Melichar
    • Medicine
    • Clinical chemistry and laboratory medicine
    • 2012
    • 4
    • PDF
    PSA and other tissue kallikreins for prostate cancer detection.
    • 80
    • PDF
    The postchemotherapy PSA surge syndrome.
    • 56
    Radical prostatectomy versus observation for localized prostate cancer.
    • 1,061
    • PDF
    Screening and prostate-cancer mortality in a randomized European study.
    • 2,221
    • PDF
    Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    • 268
    • PDF